Related Experiment Videos
Progress in cardiac transplantation
1Department of Surgery, University of Texas Medical School at Houston.
Insights
Cardiac transplantation involves recipient/donor selection, surgical techniques, and immunosuppression management. Despite coronary artery disease challenges, long-term survival rates have significantly improved.
Area of Science:
- Cardiology
- Transplant Surgery
Background:
- Cardiac transplantation is a critical treatment for end-stage heart failure.
- Managing immunosuppression and preventing complications are key to successful outcomes.
Purpose of the Study:
- To summarize current practices in cardiac transplantation.
- To highlight advancements in managing rejection and infection.
- To present institutional experience with 532 cardiac transplants.
Main Methods:
- Review of general practices in cardiac transplantation.
- Inclusion of recipient and donor selection criteria.
- Discussion of surgical techniques and perioperative management.
- Overview of immunosuppression protocols and advancements.
Main Results:
- Coronary artery disease remains the primary cause of late mortality.
- Improved immunosuppressive regimens, antiplatelet, and lipid-controlling drugs are utilized.
- Long-term survival rates following cardiac transplantation have markedly improved.
Conclusions:
- Cardiac transplantation protocols continue to evolve.
- Ongoing management of coronary artery disease is crucial for long-term patient survival.
- Institutional experience demonstrates improved outcomes in cardiac transplantation.
Abstract:
This article summarizes general practices in cardiac transplantation, including the selection of recipients and pretransplant management, selection of donors, surgical technique, management of perioperative complications, and induction and maintenance protocols for immunosuppression. Advancements in the management of rejection and infection also are included. Coronary artery disease is the most frequent cause of late death in spite of improved immunosuppressive regimens, antiplatelet agents, and lipid-controlling drugs. Still, long-term survival has improved markedly. A brief description of the Texas Heart Institute experience with 532 cardiac transplants is provided.